In the study conducted on cell models (murine and human), it was shown [106] that the use of HSP90 inhibitors (ganetespib and onalespib) in different CRPC genotypes and phenotypes affects the inhibition of oncogenic cell signaling mechanisms regulating tumor growth and development. The gene discussed is HSP90AA1; the disease is neoplasm.